Werfen Invests in Rock Health and The Sustainable Development Umbrella Fund

Werfen moves forward with its venture capital subsidiary. The company specialized in diagnosis has completed two new operations with the investment of approximately five million each in the Rock Health funds and The Sustainable Development Umbrella Fund (Sfud), which is part of the European Investment Fund (FEI), according to Expansión .

Rock Health is a venture capital fund and consulting firm based in San Francisco (United States). The company, led by its co-founder Bill Evans, specializes in the digital health sector and invests in seed and larger rounds.

Sfud is a vehicle owned by the European Union that is intended for institutional investors such as companies, insurers, pension funds and sovereign wealth funds. The fund is specialized in the health and life sciences sector and has the FEI as advisor and manager of the activity.

If you want to read more about Werfen and find the most important financial news of the day, download for free the Born2Invest mobile app. Our companion app keeps its readers up to date with the most important market updates.

Werfen achieved a turnover of €1.84 billion in 2022

We Venture Capital, Werfen’s subsidiary, started at the end of last year with an investment in the sepsis diagnostic company DeepUll. The company, promoted by Jordi Carrera and Rafael Bru, founders of StatDx, raised a financing round of €17 million that included other investors such as Sabadell Asabys, Alta Life Sciences and Kurma Partners, among others.

The second operation was closed last summer with the entry into the Belgian company Axithra , which has created a technological platform to measure and control drug concentrations in the blood.

We Venture Capital’s strategy is to carry out between three and four operations a year, with investments of around five million euros. The company will alternate interest in emerging companies with specialized funds and an international focus.

Werfen is chaired by Marc Rubiralta and in 2022 it achieved a turnover of €1.84 billion. In the largest operation in its history, the group closed the purchase of the American diagnostic company Immucor for €2 billion in March. The company’s workforce is made up of 7,000 people and its activity covers thirty countries.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.